Could a daily pill slow kidney failure in fatty liver patients?

NCT ID NCT07391267

Not yet recruiting Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether oral semaglutide, a drug already used for diabetes, can slow kidney disease in people who also have fatty liver disease. About 90 adults with both conditions will receive either the drug or standard care for 2 years. Researchers will track kidney function, liver health, and heart risks to see if the drug offers extra protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES MAFLD

Contacts and locations

Locations

Institute of Liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.